Systemic and topical antiviral treatment for CMV anterior uveitis (STACCATO)
Official title: Systemic and Topical Antiviral Control of Cytomegalovirus Anterior uveitis: TreatmentOutcomes (STACCATO)
Funded at University of California, San Francisco · NIH-11517254 · Data updated 2026-11-12
A new NIH-supported effort will test how well oral and eye-applied antiviral medicines control CMV-related anterior uveitis in affected patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | June 1, 2026 |
| Project end | January 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $16,740 |
| NIH project number | 3UG1EY036344-01A1S4 |
| Project ID | NIH-11517254 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients diagnosed with CMV anterior uveitis who may benefit from antiviral therapy and can participate in follow-up visits.
✕Less likely to help
Patients with CMV anterior uveitis who do not require antiviral treatment or cannot adhere to the study follow-up.
What this research studies
This project focuses on CMV anterior uveitis, a cause of eye inflammation that can lead to vision loss. Researchers will compare systemic (oral) antiviral therapy with topical eye drops and other approaches to see which keeps the eye healthy with manageable side effects. The study aims to clarify the best treatment strategy for immunocompetent patients, including those of Asian ancestry who appear at higher risk. By enrolling patients and following outcomes over time, the team seeks clearer guidance for clinicians and patients. The work is designed to inform practical, real-world treatment choices for CMV-related eye disease.
Why it matters
Potential benefit: If successful, patients could receive more effective, safer, and simpler treatment options to preserve vision.
How similar studies have gone: Past studies suggest potential benefits from antiviral therapy, but there is a need for randomized comparisons to define the best approach.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Gonzales, John Alexander — University of California, San Francisco
- Study coordinator: Gonzales, John Alexander
Related research
Other NIH-funded projects on the same topics.
-
Adalimumab Dose Adjustment for Pediatric Uveitis in JIA
A pediatric study will test whether lowering how often kids with juvenile idiopathic arthritis–related uveitis take adalimumab can keep inflammation controlled while reducing side effects and cost.
-
Changing adalimumab dosing for children with juvenile arthritis–related eye inflammation
This project tries to see if giving lower or less frequent doses of adalimumab can keep eye inflammation under control in children with juvenile idiopathic arthritis.
-
Systemic and topical antiviral treatment for CMV anterior uveitis in patients
A patient-friendly look at using antiviral medicines to treat CMV-related eye inflammation and protect vision.
-
Systemic and topical antiviral treatment for CMV anterior uveitis
This project tests how oral and eye-drop antiviral medicines can help prevent vision loss from CMV-related eye inflammation in people with anterior uveitis.
-
Systemic and topical antiviral control of CMV anterior uveitis: TreatmentOutcomes
A patient-focused look at how CMV eye inflammation in adults could be treated with pills, eye drops, or other strategies to prevent vision loss.
-
AI tool to standardize how uveitis is measured
This project builds an AI platform to consistently measure signs of posterior uveitis in lab models so researchers can compare and improve treatments for people with uveitis.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.